Evaluating AI-Generated Molecules for Drug Discovery: From Generic Metrics to Translational Readiness
International Journal of Molecular Sciences · 30.06.2026 · 27 (13) · 5916
DOI: 10.3390/ijms27135916 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.06.2026. Verfasst von Xiaomeng Liu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Artificial Intelligence Driven Drug Discovery, Faculty of Applied Sciences, Macao Polytechnic University, Rua de Luís Gonzaga Gomes, Macau…. Hauptthemen laut MEDLINE: Drug Discovery, Artificial Intelligence. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Development Fund.
Abstract (Originalsprache)
Artificial intelligence-driven molecular generation has become an increasingly used computational approach for proposing candidate chemical structures in early-stage drug discovery, yet the practical value of the molecules produced is often difficult to judge. Many studies still rely mainly on model-level metrics such as validity, uniqueness, novelty, and diversity. These metrics describe whether a generator produces parsable, non-redundant structures that extend beyond a reference set, but they do not show whether the molecules are chemically credible, biologically relevant, or experimentally actionable. AI-generated molecules are best treated as testable hypotheses requiring staged, complementary evidence rather than judgments based on generic generative statistics. We discuss the interpretive limits of common metrics, examine complementary levels of evaluation including medicinal chemistry feasibility, target relevance and prediction reliability, structure-based plausibility, and translational readiness, and identify recurring failure modes such as false novelty, reward exploitation, predictor bias, docking overinterpretation, and selective reporting. We propose a six-stage, failure-aware evaluation framework spanning molecular correctness, medicinal chemistry feasibility, novelty and diversity in context, target relevance and prediction reliability, structure-based plausibility, and translational readiness. This framework does not replace experimental validation; instead, it helps align computational claims with the strength of supporting evidence and promotes more transparent and reproducible evaluation of AI-generated molecules in drug discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre for Artificial Intelligence Driven Drug Discovery, Faculty of Applied Sciences, Macao Polytechnic University, Rua de Luís Gonzaga Gomes, Macau SAR, China.
ORCID-Profile: Huanxiang Liu
Förderung
- Science and Technology Development Fund
Zitieren
APA
Liu, X., & Liu, H. (2026). Evaluating AI-Generated Molecules for Drug Discovery: From Generic Metrics to Translational Readiness. International Journal of Molecular Sciences, 27(13), 5916. https://doi.org/10.3390/ijms27135916
Vancouver
Liu X, Liu H. Evaluating AI-Generated Molecules for Drug Discovery: From Generic Metrics to Translational Readiness. International Journal of Molecular Sciences. 2026;27(13):5916. doi:10.3390/ijms27135916
BibTeX
@article{Liu2026,
author = {Liu, Xiaomeng and Liu, Huanxiang},
title = {Evaluating AI-Generated Molecules for Drug Discovery: From Generic Metrics to Translational Readiness},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {13},
pages = {5916},
doi = {10.3390/ijms27135916}
}
EUVIMED